Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen‐Hua Liu, Jia‐Horng Kao, Chia-Sheng Huang et al.|Hepatology International|2021Cited by 32
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Chung‐Feng Huang, Ming‐Lung Yu, Hsueh‐Chou Lai et al.|The American Journal of Gastroenterology|2020Cited by 27
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated SubstitutionsChung‐Feng Huang, Ming‐Lung Yu, Chao‐Hung Hung et al.|The Journal of Infectious Diseases|2019Cited by 19
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort studyShou‐Wu Lee, Sheng‐Shun Yang, Pei‐Chien Tsai et al.|Clinical and Molecular Hepatology|2025Cited by 9